Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Unicycive Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +1 vs. Q1 2024
- Shares held
- 19.0M
- −2.25M (−10.6%) vs. Q1 2024
- Total value
- $9.52M
- −$22.1M (−69.9%) vs. Q1 2024
- New holders
- 5
- 6 more added
- Sold out
- 4
- 7 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 79 | $54.6M |
| Q1 2026 | 51 | $65.2M |
| Q4 2025 | 35 | $47.5M |
| Q3 2025 | 30 | $27.4M |
| Q2 2025 | 20 | $24.6M |
| Q1 2025 | 29 | $34.5M |
| Q4 2024 | 31 | $49.0M |
| Q3 2024 | 29 | $19.1M |
| Q2 2024 | 24 | $9.52M |
| Q1 2024 | 23 | $31.6M |
| Q4 2023 | 16 | $11.3M |
| Q3 2023 | 16 | $12.2M |
| Q2 2023 | 15 | $1.38M |
| Q1 2023 | 13 | $3.54M |
| Q4 2022 | 9 | $428.3K |
| Q3 2022 | 12 | $571.0K |
| Q2 2022 | 15 | $992.0K |
| Q1 2022 | 12 | $1.48M |
| Q4 2021 | 12 | $2.30M |
| Q3 2021 | 10 | $3.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 1 | $1 | 0.00% | −4,386−100.0% | Reduced |
| JPMorgan Chase & Co | 70 | $35 | 0.00% | +23+48.9% | Added |
| Bank of America Corp | 223 | $112 | 0.00% | +223 | New |
| Redwood Wealth Management Group, LLC | 3,000 | $1.50K | 0.00% | +3,000 | New |
| Scientech Research LLC | 10,969 | $5.50K | 0.00% | +10,969 | New |
| Virtu Financial LLC | 11,094 | $6.00K | 0.00% | −14,988−57.5% | Reduced |
| Tandem Capital Management Corp | 15,500 | $7.08K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 18,485 | $9.26K | 0.00% | +10,807+140.8% | Added |
| Captrust Financial Advisors | 18,800 | $9.42K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 23,998 | $12.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 33,200 | $16.6K | 0.00% | −59,660−64.2% | Reduced |
| State Street Corp | 43,936 | $22.0K | 0.00% | +8,900+25.4% | Added |
| BlackRock Inc. | 51,837 | $26.0K | 0.00% | +51,837 | New |
| LPL Financial LLC | 85,000 | $42.6K | 0.00% | +85,000 | New |
| Goldman Sachs Group Inc | 93,352 | $46.8K | 0.00% | +130.0% | Added |
| Geode Capital Management, LLC | 285,738 | $143.2K | 0.00% | +32,545+12.9% | Added |
| Monashee Investment Management LLC | 1,000,000 | $501.1K | 0.06% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,138,220 | $570.4K | 0.00% | +798,360+234.9% | Added |
| Rosalind Advisors, Inc. | 1,571,200 | $787.3K | 0.62% | −308,446−16.4% | Reduced |
| BVF Inc | 2,200,000 | $1.10M | 0.03% | −1,411,601−39.1% | Reduced |
| Ra Capital Management, L.P. | 2,632,200 | $1.32M | 0.02% | −838,488−24.2% | Reduced |
| Nantahala Capital Management, LLC | 2,820,358 | $1.41M | 0.14% | −515,228−15.4% | Reduced |
| Logos Global Management LP | 3,469,927 | $1.74M | 0.20% | 00.0% | Unchanged |
| Vivo Capital, LLC | 3,470,152 | $1.74M | 0.16% | 00.0% | Unchanged |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −69,395−100.0% | Sold out |
| Ground Swell Capital, LLC | 0 | $0 | 0.00% | −19,118−100.0% | Sold out |
| Integrated Wealth Concepts LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −196−100.0% | Sold out |